moxonidine has been researched along with Recrudescence in 1 studies
moxonidine: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with moxonidine is associated with less AF recurrences after ablation treatment for drug-refractory AF in patients with hypertension." | 5.19 | Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study. ( Deftereos, S; Doudoumis, K; Efremidis, M; Giannopoulos, G; Katsivas, A; Kossyvakis, C; Letsas, K; Manolis, AS; Panagopoulou, V; Pyrgakis, V; Raisakis, K; Rentoukas, I; Stefanadis, C; Tousoulis, D, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giannopoulos, G | 1 |
| Kossyvakis, C | 1 |
| Efremidis, M | 1 |
| Katsivas, A | 1 |
| Panagopoulou, V | 1 |
| Doudoumis, K | 1 |
| Raisakis, K | 1 |
| Letsas, K | 1 |
| Rentoukas, I | 1 |
| Pyrgakis, V | 1 |
| Manolis, AS | 1 |
| Tousoulis, D | 1 |
| Stefanadis, C | 1 |
| Deftereos, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacologic Suppression of Central Sympathetic Activity for Prevention of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation (MOXAF)[NCT01791699] | Phase 4 | 150 participants (Anticipated) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for moxonidine and Recrudescence
| Article | Year |
|---|---|
Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study.
Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Catheter Ablation; Double-Blind Method; Female; | 2014 |